Browse studies

Find your next paid study

6 recruiting studies matching your filters

Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study…

Epstein-Barr Virus InfectionsLymphomaLymphoproliferative Disorder+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT03258567

Phase 1

Phase 1 Study of the Safety of an Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

Background: Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s popula…

EBVEpstein-Barr Virus InfectionInfectious Mononucleosis+1 more

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT06908096

Phase 1

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in co…

Advanced Solid TumorsGenital Neoplasm, FemaleUrogenital Neoplasms+11 more

Estimated

~$10 – $8,750

Marengo Therapeutics, Inc.NCT05592626

Phase 1

Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells

The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomati…

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsAdenovirus+1 more

Estimated

~$10 – $6,250

Columbia UniversityNCT05183490

Phase 2

A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients

Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be admin…

Epstein-Barr Virus InfectionsPrimary Immune Deficiency Disorder

Estimated

~$10 – $6,250

New York Medical CollegeNCT03266653

Phase 1

Viral Specific T-Lymphocytes by Cytokine Capture System (CCS) to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus After Hematopoietic Cell Transplantation or Solid Organ Transplantation and in Patients With Compromised Immunity

The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenoviru…

AdenovirusCytomegalovirus InfectionsEpstein-Barr Virus Infections

Estimated

~$10 – $7,500

Jessie L. AlexanderNCT06909110